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A B S T R A C T
The interaction of cytochrome c with nitromedicines, such as 5-nitrofural, 5-nitroxoline, metronidazole
and sodium nitrite which enables the generation of nitric oxide or nitrosyl complexes in the presence
of ascorbic acid or sodium ascorbate in acid medium has been investigated. The pharmaceutical com-
positions containing cytochrome c and nitromedicine complexes as active substances were studied in
the experiments by using rats. It has been shown that positive local and systemic effects were esti-
mated when NO-containing gel was used at burn treatment. These positive effects at the local level are
due to a suﬃcient microcirculation index which indicates intensiﬁcation of the blood ﬂow in the
microvessels in the injured area. These effects at the systemic level provide maintenance of the general
heart rhythm and gradual recovery of the vegetative balance which is not observed in the animals of
the control group.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
1. Introduction
At present, nitric oxide (NO) is considered to be one of the most
important process control agents in vivo, such as endothelial re-
laxation called “endothelium-derived relaxing factor (EDRF)”, with
nerve signal transmission being the second messenger in the cel-
lular signaling pathways, gene transcription and translation [1]. For
the last thirty years it was proved that the biological variable syn-
thesis of the nitric oxide under the catalysis by NO-synthases,
including their isoforms, is related to cardiovascular and immune
system performance and ensures antibacterial, cytotoxic,
anti-inﬂammatory and antioxidant actions in vivo [2,3].
It has been estimated that some antibacterial nitromedicines are
able to release NO in vivo and in vitro under oxidation, reduction or
hydrolytic decomposition [4]. For example, the transformation of
5-nitrofurans to nitric oxide may be presented as in scheme 1 [5]:
Furan ring under reducing conditions may be able to undergo
disaromatization with the formation of radical or anion radical
species which at least partly will lead to compounds capable of re-
leasing nitric oxide. The behavior of reducing conditions in a number
of drugs nitrofuran series such as 5-nitrofural, furagin, furazoli-
done have been studied by using potassium ferrocyanide–ascorbic
acid system [5]. The evidence that the anion radicals formed in the
reduction of 5-nitrofurans are able to undergo nitro → nitrite
rearrangement was investigated in another paper [6] (scheme 2).
It has been proved that many effects associated with NO due to
peroxynitrite being the product of interaction of NO with super-
oxide anion were generated under the reduction of 5-nitrofurans.
Peroxynitrite can inhibit the electron transport chain in mitochon-
dria, disturbing the process of cellular respiration of microorganisms
resulting in antibacterial activity [4].
Nitric oxide in the intracellular ﬂuids, including bloodstream, can
interactwithavarietyof substances–thiols,metal ions, sugars– forming
different kinds of nitrosyl complexes, among them iron-nitrosyl com-
plexes,whicharevery important [7].Thenumerousexamplesof “depot”
formationofnitricoxidefromnitrosyl iron-containingcomplexes,where
the ligands were diethyldithiocarbamic, thiolate, etc., having im-
proved pharmacologic properties in comparisonwith nitric oxide, are
known [8,9]. The great contribution to the development of iron nitro-
sylcomplexeswithfunctionalsulfur-containingligandsasthenitricoxide
“depot”wasmade by the Russian scientists S.M. Aldoshin, N.A. Sanina
and some others [7,10]. The authors were the ﬁrst who systematically
investigatedthecoordinationof iron(II)byS-functionalaza-heterocyclic
thiols using triazole, tetrazole, pyrimidin, pyridine, imidazole and its
benzo-derivatives and also by natural aliphatic thioamines, many of
which are the pharmaceutical substances, the complexes themselves
having cardioprotective and antineoplastic activity.
In spite of the success achieved in the nitrosyl complexes in-
vention domain, as potential pharmaceutical substances, there are
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diﬃculties related to bioavailability, selection of the pharmaceuti-
cal substance dose, and also solubility of the nitrosyl complexes in
aqueous medium.
The NO interaction with heme proteins, including the interac-
tion with cytochrome c, is of special interest because of the nitrosyl
complexes that are formed [11–15].
M.A. Sharpe and C.E. Cooper estimated the aerobic reactions of
nitric oxide with mitochondrial cytochrome c [13]. According to
these authors [13], NO reacts with ferrocytochrome c at a rate
of 200 M−1 s−1 to form ferricytochrome c (visible spectroscopy) and
nitroxyl anion (by trapping with metmyoglobin to form the EPR-
detectable Mb-nitrosyl complex, and by the formation of dimers in
yeast ferrocytochrome c via cross-linking of the free cysteine residue),
which reacted with oxygen to form peroxynitrite. NO binds to
ferricytochrome c to form the ferricytochrome c-NO complex. The
on-rate and the off-rate for ferricytochrome c-NO complexation were
equaled 1.3 ± 0.4 × 103 M−1s−1 and 0.087 ± 0.054 s−1, consequently. It
has been shown that the dissociation constant (Kd) of the complex
is 22 ± 7 μM. These reactions of NO with cytochrome c are likely to
be relevant to mitochondrial metabolism of NO. Ferricytochrome
c can act as a reversible sink for excess NO in the mitochondria. The
reduction of NO to NO− by ferrocytochrome c may play a role in the
irreversible inhibition of mitochondrial oxygen consumption by
peroxynitrite.
Nitrosyl complexes can modify the peroxidase activity of cyto-
chrome c and control the apoptosis, relatively [15]. Nitrosylationmay
also be an allosteric regulator of other cytochrome c functions [14].
However, studies of work by other authors [14] have shown that
cytochrome c that is endogenously nitrosylated during apoptosis
is unexpected because cytochrome c has a 6-coordinate heme that
is signiﬁcantly less reactive with NO than the 5-coordinate heme
of guanylate cyclase and cytochrome oxidase. One possible expla-
nation for this result is that cytochrome c undergoes a subtle
conformational change during apoptosis that increases the reac-
tivity of the heme iron with NO. A number of investigators have
demonstrated that cytochrome c undergoes a conformational change
when bound to anionic phospholipid vesicles that model interac-
tions of cytochrome c with the phospholipid-rich mitochondrial
membranes [16]. The conformational change involves an opening
of the heme crevice, resulting in part from the loss of the iron-
methionine 80 ligation. A similar conformational change in
cytochrome c has been detected in cells early during apoptosis [14].
The data raise the possibility that alterations in mitochondrial mem-
brane lipids during apoptosis may induce a conformational change
in cytochrome c, resulting in a 5-coordinate heme. Such a confor-
mational alteration may facilitate stable heme nitrosylation of
cytochrome c during apoptosis.
Usually cytochrome c is used as the antioxidant and the
antyhypoxant that is caused by its unique enzymatic functions such
as electron transmitter at photosynthesis, when breathing, at oxi-
dative phosphorylation and other redox processes [17]. Taking the
above mentioned into consideration, the increase in pharmacolog-
ical action of cytochrome c is expected since its biological activity
ensures the ability of metalloprotein iron-porphyrin heme to form
complexes with nitric oxide and, respectively, to inhibit apoptosis.
The general goal in this paper was to create a new topical reparant
dosage form for burn wound treatment on the base antibacterial
nitromedicines able to generate NO or nitrosyl complexes in the
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Scheme 2. The reduction of 5-nitrofurans by potassium ferrocyanide-ascorbic acid system.
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presence of cytochrome c. For this purpose we studied the
following problems:
• the estimation nitrosyl complexes of cytochrome c with
nitromedicine and the role of sodium ascorbate in the forma-
tion of nitric oxide “depot” from complexes by UV-visible spectra;
• the study of burn wound regeneration in the experiments in vivo
by rats;
• the detection of the increase of total [NOx] concentration in blood
plasma in vivo under treatment of nitromedicine-cytochrome
c-complexes;
• the estimation of useful side pharmacological effects such as
vasodilatation.
2. Experimental section
Materials and reagents. Cytochrome c (from heart
bovine) (≥95%, lot STBB7839V, Fluka (USA), Sigma-Aldrich),
tris(hidroxymethyl)aminomethane (>99.2%, lot 108387, Merck), sol-
vents (analytical grade), 5-nitrofural (>99.8%), metronidazole (>99.8%),
sodium nitrite (>99.9%), 5-nitroxolin (>99.8%), ascorbic acid (>99.9%),
phosphoric, succinic acid were purchased from Sigma-Aldrich and
used without further puriﬁcation.
NO were prepared by the addition of 2 M H2SO4 to solid NaNO2
in a Kipps apparatus. The NO gas was passed through four NaOH
(20%) traps (to remove NO2), and then through a solid CO2 trap. The
gas was collected in a buffer solution that had undergone four
vacuum/N2 deoxygenation cycles. The concentration of the NO so-
lution varied from 1.2 to 2mM. The NO2− concentrationwas generally
approximately 300 μM.
Nitrite was assayed by the Griess reaction [18]. One hundred
microliter probes or standards were added to 500 μl of 1% (w/v)
sulfanilamide in 5% (v/v) H3PO4 and 500 μl 0.15 napthylenediamine
hydrochloride. The optical density (A) was measured at 540 nm, and
the assay was calibrated using nitrite standards. Determination of
nitrite and nitrate using the Griess reaction was carried out
according to methods by using Aspergillus nitrate reductase.
Absorption spectra of aqueous solutions (nitromedicine, cyto-
chrome c, organic acids, phosphoric acid and their mixtures) were
recorded by Bio line Specord S-100 (Analytik Jena), with thickness
10mm quartz cuvette. Spectrophotometer error is 0.002 units trans-
mittance at a concentration of cytochrome c 4.5·10–5mol/L–1 in
solution, and the relative standard deviation (RSD%) was 0.9%.
Formulation of pharmaceutical composition. Composition of
gel (w, %): sodium hyaluronate – 1.0; hydroxyethylcellulose – 0.1;
sodium ascorbate – 0.1; cytochrome c – 0.05; methylparaben – 0.15;
water up to 100. Sodium nitrite (0.1–1%) was added into gel before
application. Composition of powder (w, %): cytochrome c −0.05;
sodium ascorbate – 0.1; 5-nitrofural (metronidazole, nitroxolin) –
5%; methylparaben – 0.15; starch up to 100. Pharmaceutical com-
position (gel plus sodium nitrite) should be prepared just before use.
Biomedical research. The experiment with nitromedicine con-
taining dosage form was carried out by using twenty Wistar male
rats and ten rats were used as the control group. Two groups of
animals were separated, that were exposed to contact thermal burn
under anesthesia (the burn area is 20% of the body surface) [19].
After thermal injury modeling a pharmaceutical composition which
was a complex of cytochrome c and sodium nitrite was applied to
the wound surface of the animals in the main group (n = 20) for 10
days. The animals in the control group (n = 10) were treated with
5-nitrofural-containing ointment.
The microcirculation was assessed quantitatively using the
LAKK-02 (LASMA, Russia). This device transmits continuous wave
laser light (30 mW, 890 nm) and white light (20 W, 500–900 nm)
to skin tissue near the wound, where it is scattered and collected
on the skin surface with ﬁbers of the probe. Themovement of eryth-
rocytes causes a Doppler shift, which in turn is detected by the laser
light and analyzed by the LAKK-02. This is then computed and dis-
played as the blood ﬂow velocity. The detected laser signal correlates
with the number of moving erythrocytes in tissue, blood ﬂow ve-
locity for calculation microcirculation parameters, using such
arbitrary (relative) units as perfusion units (perf. un.). The rate of
microcirculation (the microcirculation level), the regulatory
activity of its components and the degree of shunt paths partici-
pation with an allowance for the frequency range intervals of the
blood ﬂow oscillations in the rats’ microvessels were investigated
[20–22].
Heart rate variability (HRV) was studied with the help of the
“Neurosoft” (Ivanovo, Russia) system with their own adaptation of
ECG registration and results management [23]. Time parameters in-
cluded parameters such as Mo, which is the most frequent mode
of RR-cardiointerval values (RR intervals were registered for 5
minutes within 0.001 s in the morning hours in rats at rest), AMo
amplitude of modal value of RR interval set, Standard Deviation of
Normal-to-Normal (SDNN) RR intervals, tension index (TI).
Statistical treatment of the results was performed with the
Statistica 6.0 program. All heart rate variability data were given with
at least two signiﬁcant digits, except p-values (one signiﬁcant digits)
and were presented as mean relative standard deviation (RSD, %).
Two-tailed tests were used. The lower level of statistical signiﬁ-
cance was set to p = 0.05. All means were accompanied by their ±95%
conﬁdence intervals.
3. Results and discussion
3.1. UV-visible study of reaction mixture with nitromedicine
generated NO-containing complexes
Sodium ascorbate was used for a spectrum control of cyt c re-
ducing form by using absorption of α- (550 nm), β- (520 nm) and
γ- (415 nm) bands. In this case at pH 7.1, the initial oxidizing form
of cytochrome c (cyt c3+), which bands at λmax 410 nm converts to
reducing form of cyt c2+ in full (Fig. 1a). Fig. 1b shows the changes
of UV-visible spectrum of aqueous solution of cyt c following the
addition of gaseous NO during 15 minutes. The shift of γ-band at
410 nm to 415 nm characterized reducing formwas observed. More-
over, new intensive band at 358 nm, two weak bands – 520 nm (β)
and 550 nm (α) typical for cyt c2+ –appeared.
The same spectral effect was estimated when cyt c was inter-
acted with nitrite at pH 3 in the work [24]. At this pH the UV as
well as visible spectrum of cyt c was changed by nitrite, even in the
presence of hydrogen peroxide, probably via the formation of heme
iron-nitric oxide complex. This spectrum argument of a heme nitric
oxide complex of cyt c had been reported previously by Orii and
Shimada (1978) and Butt and Keilin (1962). Due to this change, the
peroxidase activity of cyt c was lost.
The similar change of the heme structure of cyt cwas shown by
absorption spectra in theUV visible range in alternative system, con-
taining a mixture of cyt c, sodium nitrite and sodium ascorbate in
acidmedium, able to generatenitric oxide (Fig. 2a). TheUV-Vis spectra
of the reactionmixtureswith succinic acid are represented in Fig. 2a.
We can see the shift of γ-band from 410 nm to 415 nm, the appear-
ance of new intensive band at 358 nm, weak α- and β-bands such
as in the spectrum of cyt c3+ under gaseous NO action (Figs. 1,2). The
signiﬁcant differences of cyt c spectra of reaction mixtures, con-
taining sodium ascorbate and nitrite at pH 5.0, had the reversible
shift of γ-band from415 nmto410 nmina time–30minutes (Fig. 2b).
At the same time, a new band at 358 nm was changed in a slight
variation of time, but α- and β-bands disappeared.
The type and character of spectra depended on pH medium
and biogenic acid nature. Analysis of spectra data of the reaction
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mixtures was performed by comparing with the solutions without
sodium nitrite to establish the role of NO-donated component
(Table 1).
We suggest that the UV-visible spectra are not only indicated
on the changes of heme from cyt c3+ to cyt c2+, but also the forma-
tion of different nitrosyl cyt c complexes with nitric oxide, nitrite
(NO2–), nitroso- (NO–) or nitroxyl (NO+) ions according to the scheme
are described in the paper [1].
cyt NO cyt NOc c3 3+ ++ ↔ − (1)
cyt NO cyt NOc c3 2+ + +− ↔ − (2)
cyt NO OH cyt NO H Oc c2 2 2 22+ + − + −− + ↔ + + (3)
cyt NO cyt NOc c2 3+ + −+ → + (4)
The interaction cyt c with nitrite-ascorbate system in acid
medium, probably, lead to two types complexes – NO-cyt c2+
(λmax 415 nm) and nitrosyl cyt c2+-NO+ (λmax 385 nm), but NO-cyt
c2+-complex is not stable and converts to NO-cyt c3+ complex (λmax
410 nm).
The antibacterial nitromedicines (5-nitrofural, 5-nitroxoline, met-
ronidazole) also formed complexes with cyt c in the presence of
sodium ascorbate at pH 7.
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Fig. 1. a, b. UV–visible spectra of 2.4 μM cyt c solution after addition: (a) 5.10−4M sodium ascorbate (reducing form); (b) nitric oxide: curve 1 – reaction mixture; curve 2 –
cyt c in water (oxidizing form). Insert shows visible part of spectrum of cyt c after NO treatment.
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Fig. 2. a, b. UV-Vis spectra of 1·10−5M cytochrome c solution, 1.45·10−2M sodium nitrite, 5·10−4 sodium ascorbate, 8.5·10−3M succinic acid (curve 1) and in the absence of
sodium nitrite (curve 2); the spectra of reactions mixture in time (panel b). The insert shows dependence λ = f (τ).
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It has been shown by UV-visible spectra that the absorbance of
nitromedicine in the range of 270 nm (C = O of ascorbate) was
strongly decreased and in the range of absorption of γ-band of cyt
c3+ was changed from 410 nm up to 415 nm for all nitromedicines,
and the absorbance intensity was increased linearly when the
nitromedicine concentration was increased too. In Fig. 3a,b these
data demonstrated the formation of NO-cyt c2+-complex from cy-
tochrome c and nitromedicines, with 5-nitrofural as an example.
The complexation of cyt c2+ with nitromedicine and later on with
NO in reaction mixture during the initial ten minutes was sug-
gested by the determination of total [NOX]-concentration which
equaled 15 ± 5.4 μM at C5-nitrofural = 30 μM and 22 ± 5.8 μM at
C5-nitrofural = 60 μM, respectively.
It is necessary to note that NO-cyt c2+ complexes formed by
nitromedicine are very stable: the absorbance of reaction solution
didn’t change during one mouth.
These results allowed us to propose two types of the dosage form
on base nitromedicine, including sodium nitrite, cytochrome c
and sodium ascorbate as pharmaceutical substance: powder,
combined dosage form gel consisting of gel and powder of sodium
nitrite. The pharmaceutical composition was made directly before
the study by adding the sodium nitrite into the gel while mixing
thoroughly.
3.2. The biological activity of the pharmaceutical compositions in
the experiment on rats
3.2.1. Regeneration effects of combined dosage form (cyt
c-containing gel plus sodium nitrite)
[NO2–] concentration in “NO”-gel didn’t change during 60minutes,
but [NOx] didn’t change signiﬁcantly for one day, if NaNO2 powder
was added right after into gel-base with cyt c and sodium ascor-
bate. “NO”-gel was used only freshly prepared in all days of the
experiment.
Rat skin surface concentration of [NOx] of combined gel was equal
to 1.81 ± 0.21 μM/cm2, taking note that the average mean of surface
area of wound equaled 40 cm2 and 0.5 mL gel that treated the rat
wound . Under “NO”-gel treatment of burnwound during 30minutes
[NOx] concentration in plasma was changed from 4.82 ± 0.34 μM
as soon as the onset of injury to 5.91 ± 0.25 μM of approximating
control (Table 2).
The area of skin wounds in the experimental group decreased
under “NO”-gel treatment much faster than in the control group
(Fig. 4). While the average time of complete wound healing in the
Table 1
UV-Vis data of the aqueous reaction mixtures of 1·10−5 M cytochrome c, 5·10−4 M sodium ascorbate, 6.6·10−5 M biogenic acid at different pH in 40
minutes.
Acid NaNO2, 1.45·10−2M pH 410–415 nm 350–360 nm
λmax A λmax, nm A
no band - 7.1 415 0.60 ± 0.02 no band no band
+ 415 0.60 ± 0.02 358 0.21 ± 0.02
Succinic - 4.5 410 0.40 ± 0.02 no band no band
+ 413 0.45 ± 0.02 358 0.22 ± 0.02
Oxalic - 4.3 410 0.43 ± 0.03 no band no band
+ 412 0.46 ± 0.03 359 0.20 ± 0.02
Tartaric - 4.4 411 0.42 ± 0.03 no band no band
+ 411 0.41 ± 0.03 359 0.22 ± 0.02
Citric - 4.3 413 0.44 ± 0.03 no band no band
+ 410 0.40 ± 0.03 359 0.21 ± 0.02
no band, In the experiment in the absence of biogenic acid and sodium ascorbate λmax = 410 nm, A = 0.40 ± 0.02 (pH 6.2).
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Fig. 3. UV-Vis spectra of aqueous solutions of 1·10−5M cyt c and nitrofural. (a). Concentration of 5-nitrofural (mol/L) 1 – C = 0; 2 – C = 3.0·10–5; 3 – C = 6.0 10−5; C(cyt c) = const;
(b). Dependence of A (in the region of γ-band of cyt c) on C (nitrofural). C (Na-Asc) = 5·10−4M.
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control group was equal to 29.15 ± 1.71 days, such term of the
“NO”-gel treatment wound decreased to 21.17 ± 1.32 days.
On the third day after thermal injury under “NO”-gel treat-
ment the skin wound of the rats got better. There were great
differences in the skin wounds at tenth and third days under
“NO”-gel treatment (Fig. 4B,D).
The same result of burn wound healing was achieved when phar-
maceutical composition with other nitromedicines (5-nitrofural,
5-nitroxoline, metronidazole) was used.
3.2.2. Vasodilatation effect of “NO”-gel
With the local microcirculation assessment, the application of
the tested pharmaceutical composition proved maintenance of an
increased microcirculation index in the area around the wound on
both the third and tenth post-burn days (Fig. 5).
At the same time the animals in the control group showed
marked depression of microcirculation (p < 0.05 relative to the level
of the intact animals and the members of the main group) on the
3rd day, with partial recovery by the 10th day after the thermal
injury. At the same time it is in the early period when the most ef-
fective stimulation of regenerative processes is provided which is
triggered through NO-dependent mechanisms [3,22,23].
It should be mentioned that the level of the microcirculation
index of the rats in the control group practically returned to the
values characteristic of the intact animals, whereas it remained el-
evated (p < 0.05) in the main group, optimizing conditions for skin
regeneration.
The analysis of the parameters of heart rhythm variability allowed
us to determine that on the 3rd day after the thermal injury, the
animals in the control group gave a stress response, whereas the
rats treated with NO-containing composition showed less marked
vegetative changes with parasympathetic stimulation emphasis
(Fig. 6).
Thus, the members of the control group showed change with the
shift to the sympathetic side on the third post-burn day, but when
using a NO-containing composition, the ratio between the tension
index reﬂecting the myocardium sympathetic stimulation and the
mode amplitude visualizing vagotonic effects, corresponded, on the
whole, to the initial level. On the 10th day heart rhythm structure
optimization in the rats of both groups was observed.
The most marked tendencies are seen with respect to the spec-
tral parameters of heart rhythm variability, the ratio of spectrum
power in low- and high-frequency range, in particular (Fig. 7).
It was established that on the 3rd and 10th days of the
postburn period, marked hypersympathicotonia was found in
the animals in the control group (up to 0.2 relative units) while it
was signiﬁcantly lower in the rats of the main group, a tendency
to the normalization of the speciﬁed index being registered on the
10th day after injury.
We think that the positive effects in the wound healing are due
to not only to the action of NO or nitrosyl containing cytochrome
c-complexes, but the excess of antioxidant-sodium ascorbate in phar-
maceutical composition because metabolism of NO and related
N-oxides in the systemic circulation depends on concentration of
blood antioxidants. When human plasma is exposed to NO or NO2,
a rapid loss of antioxidants, such as ascorbic acid, uric acid andmost
importantly protein thiols, occurs [25].
4. Conclusion
In this paper we suggested new combined dosage forms of cy-
tochrome c nitrosyl complexes which consist of hydrophilic gel of
cytochrome c and powder of antibacterial nitromedicine, such as
Table 2
Total [NOx] concentration in blood plasma of rats during
“NO”-gel treatment.
[NOx], μM
Control 6.81 ± 0.22
“NO”-gel after injury (τ = 2 min) 4.82 ± 0.34
“NO”-gel treatment (τ = 30 min) 5.91 ± 0.25
“NO”-gel treatment (10 days) 6.51 ± 0.23
Control group “NO”-gel
3rd day after burn 3rd day after burn
10th day after burn 10th day after burn
D
A
C
B
Fig. 4. Healing of the burn wounds: (A) 3rd day after burn in control group; (B) under “NO”-gel treatment during third day; (C) 10th day after burn in control group;
(D) under “NO”-gel treatment during tenth day.
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Day Level of microcirculation, PM, perf. un. RSD, %
Control 3 6,18±0,02 0,25
“NO”-gel 3 10,65±0,02 0,19
Control 10 9,25±0,05 0,38
“NO”-gel 10 11,90±0,02 1,30
0
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control NO-containing
gel
control NO-containing
gel
intact the third day after the burn the tenth day after the burn
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Fig. 5. The inﬂuence of topical treatment by “NO”-gel on level microcirculation (LM, perf. un.) in periwound area of animals. Level of microcirculation was estimated by
laser Doppler ﬂowmetry in third and tenth days after burn. The level microcirculation is the microcirculatory rate presented in perfusion units (perf. un.); *, the statistical
differences of control and main (with “NO”-gel) groups, p < 0.05; #, the statistical differences of control and intact groups, p < 0.05.
Day TI, stand. units AMo, stand. units
Control 3 40,0±2,5 32,8±2,3
“NO”-gel 3 18,1±1,8 57,0±4,0
Control 10 26,1±1,3 50,7±4,2
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“NO”-gel 10 26,6±1,4 36,9±2,5
Fig. 6. The dependence of heart rate variability (HRV) parameters on the topical treatment of rats with thermal injury (SI, stress index, AMo, amplitude of modal value of
RR interval set). Heart rate variability was estimated by special Neurosoft ECG system in third and tenth days after burn. The rate of stress index and amplitude of modal
value was demonstrated in relative units (rel. un.); *, the statistical differences of control and main (with “NO”-gel) groups, p < 0.05; #, the statistical differences of control
and intact groups, p < 0.05.
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5-nitrofural, metronidazole, 5-nitroxolin, and sodium nitrite, for burn
wounds treatment.
The formation of cytochrome c nitrosyl complexes in the reac-
tions with nitromedicine was proved in comparison with reaction
mixtures of cytochrome c and gaseous nitric oxide, in the pres-
ence of sodium nitrite as the nitric oxide “depot” by using UV-
visible spectra. Ascorbic acid may promote the complexation of
ferrocytochrome c with nitromedicines in aqueous solutions too.
It has been shown that absorption of γ-band (415 nm) typical for
ferricytochrome c linearly increased with medicine concentration,
but ascorbic acid absorption band extremely decreased in the region
of 270 nm and new bands of nitrosyl content compounds in the
region of 350–390 nm appeared.
With the use of rats in the experiments, the vasodilatation and
regeneratting effects were shown when the wounds were treated
with a combined dosage form of cytochrome c and nitromedicine
on the base complexes, thus being able to generate nitric oxide. These
positive effects at the local level are shown by a suﬃcient micro-
circulation index which indicates intensiﬁcation of the blood ﬂow
in the microvessels in the injured area [26]. The effects at the sys-
temic level provide maintenance of the general heart rhythm and
gradual recovery of the vegetative balance, which is not observed
in the animals of the control group.
The developed combined dosage form has the advantages over
reparant ointments that usually are used because they show pos-
itive local and systemic effects. We suppose that pharmaceutical
composition containing cytochrome c, sodium ascorbate and
nitromedicine may be used as transdermal dosage forms for
cardiological disease treatment in the future.
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Control 3 0,21±0,02 0,31
“NO”-gel 3 0,38±0,03 0,11
Control 10 0,22±0,01 0,57
“NO”-gel 10 0,46±0,03 0,82
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
control NO-containing
gel
control NO-containing
gel
intact the third day after the burn the tenth day after the burn
L
F
/H
F
 r
at
io
, r
el
. u
n
# # 
* # 
* # 
Fig. 7. The dependence of ratio LF/HF on the topical treatment of the animals with
thermal injury; LF (ms2) and HF (ms2) mean power of heart rate in low (LF)- and
high-frequency (HF) range. The ratio LF/HF was shown in relative units (rel. un.);
*, the statistical differences of control and main (with “NO”-gel) groups, p < 0.05;
#, the statistical differences of control and intact groups, p < 0.05.
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